Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry
Pediatric Dermatology · 18.08.2026
DOI: 10.1111/pde.70335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, online erschienen am 18.08.2026. Verfasst von Amy S Paller und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background/Objective The multifactorial disease burden of moderate‐to‐severe atopic dermatitis (AD) may affect children's growth. We report height, weight, and body mass index (BMI) of children under 12 years old with moderate‐to‐severe AD in comparison to the general population.
Methods
This was a cross‐sectional analysis of enrollment data from PEDISTAD, a global real‐world observational study of pediatric patients < 12 years old with moderate‐to‐severe AD.
Results
Among the 1329 children with moderate‐to‐severe AD, 72% of male children 5 to < 12 years were below the 50th percentile for height, as were 53% of females in this age group. In contrast, the weight of children 5 to < 12 years was above the 50th percentile in 56% of males and 52% of females, resulting in above‐average BMI values. In the 0 to < 5 years old age groups, height and weight were above the 50th percentile for 59% and 50% of female children, and 52% and 42% of male children, respectively.
Conclusions
This real‐world observational study showed in children 5 to < 12 years old with moderate‐to‐severe AD that the average height was lower than the US 50th percentile, with a more pronounced reduction in male children. Additionally, higher weight and, as a result, higher BMI were observed in the children included in this analysis. Trial Registration: ClinicalTrials.gov identifier: NCT03687359
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- School of Medicine, Trinity College Dublin, Dublin, Ireland.
- Hospital Sant Joan de Déu, Barcelona, Spain.
- Department of Dermatology, University Medical Center Utrecht, Utrecht, the Netherlands.
- Saint Louis University, St. Louis, Missouri, USA.
- Cardinal Glennon Children's Hospital, St. Louis, Missouri, USA.
ORCID-Profile: Amy S Paller, Alan D Irvine, Eulalia Baselga, Marlies de Graaf, Elaine C Siegfried, Michele Ramien, Lawrence F Eichenfield
Förderung
- Sanofi
- Regeneron Pharmaceuticals
Zitieren
APA
Paller, A. S., Irvine, A. D., Baselga, E., de Graaf, M., Siegfried, E. C., Cork, M. J., Ramien, M., Eichenfield, L. F., Adams, B., Gupta, R., Ardeleanu, M., & Zhang, A. (2026). Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry. Pediatric Dermatology. https://doi.org/10.1111/pde.70335
Vancouver
Paller AS, Irvine AD, Baselga E, de Graaf M, Siegfried EC, Cork MJ, et al. Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry. Pediatric Dermatology. 2026. doi:10.1111/pde.70335
BibTeX
@article{Paller2026,
author = {Paller, Amy S and Irvine, Alan D and Baselga, Eulalia and de Graaf, Marlies and Siegfried, Elaine C and Cork, Michael J and Ramien, Michele and Eichenfield, Lawrence F and Adams, Bryan and Gupta, Rajan and Ardeleanu, Marius and Zhang, Annie},
title = {Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry},
journal = {Pediatric Dermatology},
year = {2026},
doi = {10.1111/pde.70335}
}
EUVIMED